Contributing Member of the Healthcare Councils

Names and details of certain GLG News authors are available only to GLG Clients and Council Members. GLG News authors are subject-matter experts within the GLG Councils and are available for expert consulting - by phone, in-person, or written analysis. To find out how to become a GLG client or Council Member, click here.

GLG News by this Author

Analyses are solely the work of the authors and have not been edited or endorsed by GLG.

GLG News is now G+ Insights

G+ is a community for professionals, academics and entrepreneurs to connect through online discussions and in-person meetings. You will continue to see G+ Insights (formerly GLG News) here as well as on the G+ website, where you can share and discuss the G+ Insights you read.

Fresh Hope for Diabetes Patients

October 15, 2009

Analysis of:ONGLYZA™ (saxagliptin) Receives Marketing Authorisation In Europe For The Treatment Of Type 2 Diabetes | www.pipelinereview.com

The success of ONGLYZA (saxagliptin) will largely depend on its long-term safety. Saxagliptin is the second drug from this class to be approved in Europe and the US - Merck's Januvia (sitagliptin) was the first. Saxagliptin has had to overcome several new regulatory hurdles as a result of major recent safety issues with other diabetes drugs including sitagliptin. Sceptical prescribers and heavy postmarketing scrutiny will likely mitigate a rapid uptake.

Page : 11 to 1 of 1

Subscribe to Updates

By RSS